+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Therapeutic Breakthroughs in Multiple Sclerosis

  • ID: 4308292
  • Report
  • 15 pages
  • Frost & Sullivan
1 of 2
This edition of the Future Tech TOE primarily encompasses comprehensive analyses of key emerging therapies across multiple sclerosis (MS). The service also includes treatment overviews, clinical pipeline analysis, IP and funding analysis, and emerging innovations across MS therapies. Furthermore, the research features the impact of key technology drivers and restraints for the global MS therapeutic industry, while providing an overview of the emerging technological landscape for MS treatments.

The Future Tech TechVision Opportunity Engine (TOE) captures emerging innovations in research and development, or profile existing technologies which have seen a resurgence in terms of new markets and applications. It usually provides a technology overview, drivers, challenges, research and development, analyst insights and key patent information. In some cases, technology convergence scenarios and future growth opportunities are outlined. It covers innovations and technologies in a variety of industry spaces including manufacturing, sensors, electronics, information and communications technologies, networks, lighting technologies, healthcare, medical devices, materials and coatings, and developments in the energy sector that contribute toward a sustainable and greener world.

The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Note: Product cover images may vary from those shown
2 of 2
1. Overview of Multiple Sclerosis Treatments
1.1 New Therapies on the Horizon for Multiple Sclerosis
1.2 Summary of Existing Disease Modifying MS Therapies
1.3 Overview of Emerging MS Therapies
1.4 Role of Stem Cell Therapy in MS Management
1.5 Clinical Pipeline Overview for Late Phase MS Therapies
1.6 Clinical Pipeline Overview for Early Phase MS Therapies

2. Innovation Tracker
2.1 Breakthrough Approval for Roche’s Ocrelizumab
2.2 Novartis’s MS Portfolio Expands with Ofatumumab Acquisition
2.3 Evaluating Oral Biotin Formulation for Progressive MS
2.4 Role of Tyrosine Kinase Inhibitor in Progressive MS
2.5 Hematopoietic Stem Cell Therapy for MS Management
2.6 Antibody Therapy for Myelin Repair

3. Impact Analysis and Assessment
3.1 Summary of Key Technology Drivers and Restraints
3.2 Growing Demand for Targeted Therapies Likely to Fuel New Discoveries across MS Management
3.3 High Risk of Treatment Toxicity Still a Major Concern across MS Management

4. Strategic Insights and Future Perspectives
4.1 US Leads the Global IP Landscape for MS Treatments
4.2 Analysis of Research Funding for MS Treatments in the US
4.3 DMTs Likely to Enhance the Future of MS Management

5. Appendix
5.1 Key Contacts
Note: Product cover images may vary from those shown
3 of 2